共 50 条
- [31] A phase 3, randomized, double-blind study of epacadostat plus pembrolizumab vs pembrolizumab as first-line therapy for metastatic non-small cell lung cancer (mNSCLC) expressing high PD-L1 levels (ECHO-305/KEYNOTE-654)JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S116 - S117Paz-Ares, L.Rubin, S.Zhao, Y.Xu, L.Samkari, A.Awad, M.
- [32] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Clay, Timothy DudleyMajem, MargaritaFelip, EnriquetaDoger, BernardCosta, Enric CarcerenyForster, MartinKrebs, MatthewPeguero, Julio AntonioMueller, ChristianTriebel, Frederic
- [33] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort studyINVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218Kawachi, HayatoTamiya, MotohiroTamiya, AkihiroIshii, SeigoHirano, KatsuyaMatsumoto, HirotakaFukuda, YasushiYokoyama, ToshihideKominami, RyotaFujimoto, DaichiHosoya, KazutakaSuzuki, HidekazuHirashima, TomonoriKanazu, MasakiSawa, NobuhikoUchida, JunjiMorita, MitsunoriMakio, TakeshiHara, SatoshiKumagai, Toru
- [34] A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Rogue, Dana M.Bellone, StefaniaSiegel, Eric R.Buza, NataliaBonazzoli, ElenaGuglielmi, AdeleZammataro, LucaNagarkatti, NupurZaidi, SamirLee, JungsooSchwartz, Peter E.Ratner, ElenaAlexandrov, Ludmil B.Iwasaki, AkikoKong, YongSong, EricDong, WeilaiElvin, Julia AndreaChoi, JungminSantin, Alessandro
- [35] A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)ANNALS OF ONCOLOGY, 2021, 32 (08) : 1045 - 1046Bellone, S.Roque, D. M.Siegel, E. R.Buza, N.Hui, P.Bonazzoli, E.Guglielmi, A.Zammataro, L.Nagarkatti, N.Zaidi, S.Lee, J.Silasi, D-AHuang, G. S.Andikyan, V.Damast, S.Clark, M.Azodi, M.Schwartz, P. E.Tymon-Rosario, J.Harold, J.Mauricio, D.Zeybek, B.Menderes, G.Altwerger, G.Ratner, E.Alexandrov, L. B.Iwasaki, A.Kong, Y.Song, E.Dong, W.Elvin, J.Choi, J.Santin, A. D.
- [36] Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancerANNALS OF ONCOLOGY, 2020, 31 : S1165 - S1165Konstantinopoulos, P. A.Gockley, A. A.Xiong, N.Tayob, N.Krasner, C. N.Buss, M.Campos, S.Schumer, S.Wright, A. A.Liu, J. F.Shea, M.Oladapo, Y.Castro, C.Polak, M. M.Whalen, C.Bouberhan, S.Cannistra, S. A.Penson, R. T.Fleming, G.Matulonis, U. A.
- [37] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center StudyPNEUMOLOGIE, 2022, 76 : S93 - S93Olive, E.Frost, N.Grohe, C.
- [38] Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)Investigational New Drugs, 2019, 37 : 1266 - 1273Motohiro TamiyaAkihiro TamiyaKazutaka HosoyaYoshihiko TaniguchiToshihide YokoyamaYasushi FukudaKatsuya HiranoHirotaka MatsumotoRyota KominamiHidekazu SuzukiTomonori HirashimaJunji UchidaMitsunori MoritaMasaki KanazuNobuhiko SawaYoshinori KinoshitaSatoshi HaraToru KumagaiDaichi Fujimoto
- [39] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756CANCER RESEARCH, 2024, 84 (09)Cardoso, FatimaO'Shaughnessy, JoyceMcArthur, HeatherSchmid, PeterCortes, JavierHarbeck, NadiaTelli, MelindaCescon, DavidFasching, Peter A.Shao, ZhiminLoirat, DelphinePark, Yeon HeeFernandez, Manuel GonzalezRubovszky, GaborIm, Seock-AhHui, RinaTakano, ToshimiAndre, FabriceYasojima, HiroyukiLiu, ZhenzhenDing, YuJia, LiyiKarantza, VassilikiTryfonidis, KonstantinosBardia, Aditya
- [40] Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1266 - 1273Tamiya, MotohiroTamiya, AkihiroHosoya, KazutakaTaniguchi, YoshihikoYokoyama, ToshihideFukuda, YasushiHirano, KatsuyaMatsumoto, HirotakaKominami, RyotaSuzuki, HidekazuHirashima, TomonoriUchida, JunjiMorita, MitsunoriKanazu, MasakiSawa, NobuhikoKinoshita, YoshinoriHara, SatoshiKumagai, ToruFujimoto, Daichi